Perrigo seeks approval for generic version of Abbott's Androgel

ALLEGAN, Mich. — Drug maker Perrigo has filed for regulatory approval of a generic topical drug for treating testosterone deficiency, prompting a patent infringement suit from the branded version's manufacturer.



Perrigo announced Wednesday that it had applied for Food and Drug Administration approval of testosterone gel in the 1% strength, a generic version of Abbott's Androgel, used to treat men with low or no testosterone. In response, Abbott filed suit against Perrigo in the U.S. District Court for the District of New Jersey on Monday, alleging that Perrigo's filing infringes Abbot's patent on the drug.



Androgel has annual sales of about $900 million, according to Wolters Kluwer Health.

Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.